Suppr超能文献

与非系统性活检相比,系统性四象限活检能在更多患者中检测出巴雷特发育异常。

Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy.

作者信息

Abela Jo-Etienne, Going James J, Mackenzie John F, McKernan Margaret, O'Mahoney Sylvia, Stuart Robert C

机构信息

Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom.

出版信息

Am J Gastroenterol. 2008 Apr;103(4):850-5. doi: 10.1111/j.1572-0241.2007.01746.x. Epub 2008 Mar 26.

Abstract

AIMS

To compare detection of Barrett's dysplasia and adenocarcinoma by systematic versus nonsystematic surveillance biopsy protocols.

METHODS

Upper GI consultation and open-access endoscopy are provided jointly at Glasgow Royal Infirmary by medical and surgical teams. The surgical team adopted annual systematic four-quadrant biopsy Barrett's surveillance in 1995. The medical team continued annual Barrett's surveillance with nonsystematic biopsy until 2004. We compare detection of Barrett's dysplasia and esophageal adenocarcinoma in unselected patients by these two biopsy strategies over 10 yr. All patients had > or = 3 cm Barrett's esophagus and histological proof of intestinal metaplasia. Patients referred for dysplasia management or with prevalent adenocarcinoma were excluded. Cohort A (N = 180) had four-quadrant biopsy every 2 cm while cohort B (N = 182) had nonsystematic biopsies.

RESULTS

Cohort A versus cohort B: Median number of biopsies per endoscopy: 16 versus 4. Prevalence of low-grade dysplasia (per patient): 18.9% versus 1.6% (P << 0.001). Prevalence of high-grade dysplasia: 2.8% versus 0% (P = 0.03). Incidence of low-grade dysplasia: 2.2% versus 6.6% (NS). Incidence of high-grade dysplasia: 2.8% versus 0% (P = 0.03). Nine cohort A patients (total 5%, 1.4% per patient-year) were treated for HGD (eight endoscopically, one by esophagectomy). Two had intramucosal adenocarcinoma. No cohort A patient developed advanced cancer but three cohort B patients developed and died of invasive Barrett's adenocarcinoma (0.6% per patient-year).

CONCLUSIONS

Patient age, gender, Barrett's segment length, and follow-up were similar (though not identical) in both cohorts, but confounding seems unlikely to account for a 13-fold difference in detection of prevalent dysplasia between the two groups. Our data support the hypothesis that systematic four-quadrant biopsy is considerably more effective than nonsystematic biopsy sampling in detecting Barrett's dysplasia and early adenocarcinoma. Greater biopsy numbers and the systematic pattern of biopsy taking may both contribute to this greater effectiveness.

摘要

目的

比较系统监测活检方案与非系统监测活检方案对巴雷特异型增生和腺癌的检测效果。

方法

格拉斯哥皇家医院的内科和外科团队联合提供上消化道会诊和开放获取式内镜检查。外科团队自1995年起采用每年一次的巴雷特食管系统四象限活检监测。内科团队在2004年前一直采用每年一次的巴雷特食管非系统活检监测。我们比较了这两种活检策略在10年期间对未选择患者中巴雷特异型增生和食管腺癌的检测情况。所有患者的巴雷特食管长度均≥3 cm,且有肠化生的组织学证据。因异型增生管理前来就诊或患有现患腺癌的患者被排除。A组(N = 180)每2 cm进行四象限活检,而B组(N = 182)进行非系统活检。

结果

A组与B组比较:每次内镜检查的活检中位数:16次对4次。低级别异型增生的患病率( per patient):18.9%对1.6%(P << 0.001)。高级别异型增生的患病率:2.8%对0%(P = 0.03)。低级别异型增生的发病率:2.2%对6.6%(无显著差异)。高级别异型增生的发病率:2.8%对0%(P = 0.03)。A组有9名患者(共5%,每年每患者1.4%)接受了高级别异型增生治疗(8例通过内镜治疗,1例通过食管切除术)。2例患有黏膜内腺癌。A组无患者发展为进展期癌症,但B组有3例患者发展为浸润性巴雷特腺癌并死亡(每年每患者0.6%)。

结论

两组患者的年龄、性别、巴雷特食管段长度和随访情况相似(虽不完全相同),但混杂因素似乎不太可能解释两组在现患异型增生检测上13倍的差异。我们的数据支持这样的假设,即系统四象限活检在检测巴雷特异型增生和早期腺癌方面比非系统活检采样有效得多。更多的活检次数和系统的活检方式可能都有助于提高这种有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验